A fosfomycin plus tobramycin combination formulation for delivery by acrosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfoinycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5 [mu], produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.
